Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 14/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364269 | 0.86 | MALT1 (0.50) | MALT1TRPV1 | |
| SCHEMBL16648570 | 0.86 | MAPT (0.64) | MALT1TRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4876457 | 0.85 | MALT1 (0.60) | MALT1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4533155 | 0.85 | MALT1 (0.54) | MALT1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL16769731 | 0.85 | MALT1 (0.64) | MALT1TRPV1KMT2A | |
| SCHEMBL2421306 | 0.83 | MALT1 (0.70) | MALT1TRPV1KMT2AKDM4E | |
| SCHEMBL14086101 | 0.83 | MALT1 (0.51) | MALT1TRPV1 | |
| SCHEMBL4103009 | 0.81 | MAPT (0.68) | MALT1SMN1; SMN2 | |
| SCHEMBL5220685 | 0.81 | MALT1 (0.64) | MALT1TRPV1MEN1KMT2A | |
| SCHEMBL30896975 | 0.81 | SMN1; SMN2 (0.52) | MALT1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | MALT1 709/4885TRPV1 1/4885MEN1 3933/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | MALT1 563/4885TRPV1 1/4885MEN1 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.